A

s a district sales manager for Insys Therapeutics, Jeffrey Pearlman led a team that aggressively pushed doctors to widely prescribe the company’s highly addictive opioid painkiller Subsys. He even threatened to stop paying a nurse speaking fees if she didn’t help boost sales of the drug, emails show.

All the while, Pearlman held a secret: He himself was addicted to opioids like the very ones he was promoting.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

  • THIS SOULD BE AWAKE UP CALL AL THE DEATHS THEY BELEIVE WILL HAPPEN FROM ILLISIT DRUG NOT CHRONIC PAIN PAIN PATIENTS SOULD TELL YOU DON’T LET US DIE LET THE DRUG DEALS AND HE PEOPLE BUSTED WITH THE FYNTANAL AND HERION SPEND LIFE IN JAIL FOR MURDER

  • off topic – but you can buy a years supply of fentanyl (aka heroin) on the street for $1500 and the dealers make a boatload of profit. The article says “The (fentanyl) drug can cost tens of thousands of dollars a year”. This is what is wrong with big Pharma, huge profits that balloon the cost of health care.

  • Stop demonizing pain medication. It is vital medicine for people who live with pain. Start by dropping the dishonest “opioids” which implies that a three-day course of Percocet is equivalent to heroin. Taking drugs just to get high is very dangerous, but a three or four day course of pain medication for a person suffering pain is good medicine. For people who live with chronic, excruciating pain, the medication is absolutely essential.

  • What is the difference between him & a street corner drug pusher??
    They go to hard time prisons & he asks for Federal waivers to continue his MJ!!

  • I don’t feel sorry for him. Just send him to jail pending trial, then he won’t be tempted by the big bad pain pills

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.